HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
Key Details
- 1AI-CVD is cleared via FDA 510(k) by HeartLung Corporation.
- 2The platform analyzes CT images of the chest and abdomen to screen for various diseases.
- 3No additional CT sequences, radiation, or contrast are needed to use the tool.
- 4Automatically quantifies clinical measurements for cardiovascular and non-cardiovascular conditions.
- 5Diseases targeted include coronary artery disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
Why It Matters
The clearance marks a significant step for opportunistic AI in radiology, enabling wider disease detection from standard CT scans without extra imaging, doses, or disruptions. This has the potential to improve early diagnosis and make radiology workflows more efficient.
Source
Radiology Business
Related News
•Radiology Business
FDA Clears Median's Eyonis AI for CT Lung Cancer Screening
Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
•AuntMinnie
Deep Learning Super-Resolution Boosts Accuracy of Coronary CT Angiography
Super-resolution deep learning reconstruction (SR-DLR) outperforms hybrid iterative reconstruction in coronary CT angiography for stenosis assessment.
•AuntMinnie
Task-Specific NLP Outperforms General LLMs for Lung Nodule Detection in Chest CT Reports
A radiology-trained NLP model significantly outperformed several general-purpose large language models in extracting incidental lung nodule data from chest CT reports.